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he KIF6 Collapse*
ric J. Topol, MD,
amir B. Damani, MD, PHARMD
a Jolla, California
ver the past 2 years, the Celera Corporation (Alameda,
alifornia) has heavily marketed its KIF6 Trp719Arg vari-
nt assay to cardiologists and primary care physicians. To
ate, 160,000 tests have been ordered in the U.S. alone at
cost of approximately $100 per test (1). Most recently,
elera has licensed 3 laboratories in Germany with plans to
xtend KIF6 testing internationally within a year. The
enomic basis for this assay stems primarily from a few
bservational studies of cohorts that demonstrated a modest
ncrease in risk of coronary artery disease (CAD) in Euro-
ean carriers of the common KIF6 719Arg variant allele
odds ratio [OR]: 1.1 to 1.5) (2–4). Interestingly, the
ROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evalu-
tion and Infection Therapy in Myocardial Infarction–
hrombolysis In Myocardial Infarction 22) trial further
emonstrated that therapy with statins abolished this in-
reased risk in those individuals with the KIF6 variant allele
2). These studies have formed the foundation for Celera’s
Statincheck,” which has been promoted as a rapid phar-
acogenetic assay that identifies individuals who will most
ikely benefit from statin therapy (1).
See page 1552
Now, Assimes et al. (5) in this issue of the Journal report
esults from a very important study strongly refuting the
IF6 link to CAD in a well-conducted and elegant meta-
nalysis involving 17,000 cases of CAD and 39,000
ontrols from 19 different studies conducted around the
orld. An independent analysis of the early-onset myocar-
ial infarction (MI) cohort and diverse ancestries also failed
o reveal any significant correlation between KIF6 and
AD. Notably, 12 of the 19 studies included in the analysis
nly enrolled cases with a documented history of MI, a
uch more clinically robust and distinct phenotype than the
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiovascular Diseases, Scripps Clinic, Scripps Transla-
ional Science Institute and the Scripps Research Institute, La Jolla, California.t
ftikhar Kullo, MD, served as Guest Editor for this paper. The authors have reported
hat they have no relationships to disclose.ore commonly used CAD (6). Further, 14 of the studies
lso restricted enrollment to individuals with early-onset
isease (women 65 years of age and younger, men 55 years
f age and younger). The vital inclusion of these genetically
nriched populations substantially enhances the power of
heir meta-analysis for detecting any potential genetic link
etween KIF6 and CAD risk and greatly limits the potential
f their results being falsely negative (6).
So what went wrong? Why have 150,000 KIF6 geno-
ypes been ordered in the past 2 years for a test that now
eems to be useless? Closer inspection of the original data
mplicating KIF6 yields several clear explanations. Fore-
ost, the original observational studies used to “firmly”
stablish the KIF6 variants association with CAD used
ntiquated candidate gene-based methodologies (2–4), a
ethod well-known to be plagued by false-positive results
nd a notorious inability for variants originally identified to
e subsequently validated in additional studies (also known
s winner’s curse) (7). To further add to existing skepticism
bout KIF6 is the lack of mechanistic studies demonstrating
he gene’s impact on atherosclerosis, lipid metabolism,
AD, or MI (8,9). Of note, the authors of the current study
ppropriately emphasize that “no consistent expression of
his gene has been demonstrated in relevant tissues such as
he vasculature” (8,9).
Today, enabled by the International Human HapMap
onsortium, we are able to simultaneously assay for
500,000 common (present in 5% of the population)
ingle nucleotide polymorphisms (SNPs) in genome-wide
ssociation studies (GWASs) for the purpose of identifying,
n an unbiased manner, genetic markers of complex trait
usceptibility that reach stringent statistical significance
hresholds (p  5  108) (10). Beyond this, replication in
ndependent cohorts is required before such evidence of
enome-wide significance of a marker can be considered
alidated. This approach, unlike previous candidate gene
ethods, has provided incontrovertible evidence of novel
AD susceptibility variants (6,10). In particular, common
NPs in apolipoprotein E, lipoprotein(a), chromosome
p21, and many other regions of the genome have been
dentified and validated as CAD susceptibility markers in
ultiple GWASs involving thousands of CAD cases and
ontrols (11–16). Further, the clear functional significance
f lipoprotein(a) and apolipoprotein E in pathways of lipid
etabolism bolsters existing GWAS evidence and supports
heir link to common forms of CAD and MI. In contrast,
o variant in KIF6 has yet emerged as a statistically
ignificant marker in 8 GWASs conducted to date on
yslipidemia, CAD, and MI (11–13,15,17–20). Such a
ommon variant (present in 35% of Europeans) should
ave clearly surfaced in these GWASs if the association was
ruly valid. In addition, all SNP arrays used in these studies
irectly genotyped the at-risk KIF6 SNP—rs20455—and
id not require imputation (Fig. 1). Therefore, even before
he publication of the current study, the association of
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November 2, 2010:1564–6 KIF6 Collapses20455 (present in 35% of Europeans) with CAD was
rguably tenuous at best.
Proponents of KIF6 testing will almost certainly continue
o argue that a high prevalence of statin use in the CAD
ases may have abrogated the KIF6 risk of CAD, and,
herefore, no significant effect for KIF6 was observed.
owever, that argument holds little merit. In fact, several of
he initial reports noting the KIF6 association with CAD
id not indicate that statin users were excluded or censored
efore their analysis (4,21,22). Further, given the 8,000
ases of early-onset disease included in the current analysis,
tatin use was most likely to be lower than in the initial
tudies used to establish the KIF6 variant as a novel
predictive” biomarker.
The final and decisive affront to the KIF6 story relates to
he unraveling of its largely unsubstantiated claims that
ariant carriers exhibit an enhanced response to statin
herapy. This premise is largely predicated on previous data
inking KIF6 to a heightened risk of CAD. However, as the
urrent study nicely demonstrates, this is not the case. Most
mportantly, no plausible biological mechanism of KIF6-
ediated statin response is currently available. This is in
irect contrast to hepatic cytochrome (CYP) 2C19 gene
ariants, which recently, through a GWAS on antiplatelet
esponse to clopidogrel, have been found to be the only
ommon variant yet identified for genomic resistance to this
idely used agent (23). To date, no such GWAS assessing
tatin response has been conducted or even initiated. Until
uch studies are conducted, pharmacogenetic tests with
laims of identifying statin hyper-responders or hypore-
ponders should be viewed with considerable skepticism.
Since the initial draft of the human genome in 2001, we
ave witnessed a14,000-fold decrease in the cost of DNA
enotyping and sequencing (24). Accompanying this dra-
atic trend has been a greatly increasing number of loci
inked to disease susceptibility and treatment response.
oing forward, such genetic and pharmacogenetic markers
Figure 1 UCSC Genome Bioinformatics Web Browser Search of
KIF6 Arg719 variant (rs20455) is directly genotyped on commonly used Illumina aust be accompanied by stringent vetting by investigators inell-designed, hypothesis-free, genome-wide studies before
romoting their use in clinical practice. Although several
ardiovascular-related genomic and pharmacogenomic bio-
arkers have clearly surpassed this important evidence thresh-
ld including the aforementioned apolipoprotein E, LPA, and
he recently identified CYP2C19 variants involved in clopi-
ogrel metabolism, the KIF6 association has lacked such data
rom the time of its initial reports. Going forward, the KIF6
tory should serve as a valuable reminder of the potential
itfalls present in prematurely adopting a genomic test
ithout sufficient evidence.
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